February 2026 saw a major biopharma acquisition, four key buyouts, and licensing deals in antibodies, small molecules, and ...

Investors are increasingly wary of the rare-disease space, spooked by a regulatory shift.

Biohackers. Longevity gurus. Wellness influencers. What do they have in common? Most place a focus on optimizing physical and mental health and performance, while maximizing lifespan along the way.

UniQure said Monday that plans to seek approval for its Huntington’s disease treatment with the Food and Drug Administration ...

The US leads the world in ag biotech, but that lead is eroding, not in the lab, but in the gap between discovery and ...

The FDA is already under fire from lawmakers for recent delays and rejections of new drugs for rare diseases.

China aims ​to boost grain production capacity to 725 million metric tons over 2026-2030, prioritizing yield gains through ...

The FDA believes that an experimental therapy for Huntington’s disease from UniQure wasn't providing benefit for patients, a senior official told STAT.

Iovance Biotherapeutics developed Amtagvi, a medicine manufactured from patients' own cancer-fighting cells. Amtagvi earned ...

Poplar Therapeutics is seeking a “step change” in the treatment of food allergy and other atopic conditions, with $95 million ...

Rare Disease Day is held on the last day of February to raise awareness for rare diseases and address drug development ...

Durham-based BioCryst Pharmaceuticals Inc. is advancing care for children living with hereditary angioedema (HAE) as it ...